Why I Bet Everything on a One-Week Decision
At twelve, I sat in front of a Sinclair Spectrum 48 and started writing programs. Nobody around me thought it would go anywhere. I just wanted to understand how far a machine would go if I told it exactly what to do.
That question shaped the rest of my career. Robot automation at Oulu University. A first company in 1991, built with friends, writing algorithms and early classification systems for industry. Twelve years as an entrepreneur, leading sales and writing code at the same time.
A sales director role in Berlin followed, running a team of twenty across Eastern Europe, Africa, the Middle East and South America. Then a decade as a business coach, including work for the European Union. Ginolis was one of my clients.
I never planned to run a MedTech company. The mission changed that. Ginolis existed to mass-produce the latest diagnostics technology, and that combination- automation, medicine, and real-world impact- was hard to walk past.
So when the previous owners decided to sell, and the window was one week, I didn't hesitate. I called two investors that evening. Both said yes by the next morning. What I was really committing to was a market thesis I had already spent years studying, and something I couldn't put down.
The mission got to me before the balance sheet did.
In the years since, that decision has looked increasingly like the right one. Ginolis is now fifteen years old, with roots in electronics manufacturing automation. We have delivered more than 150 automated production lines across 37 countries, producing over 100 million diagnostic products a year.
When I arrived, customers kept describing the same problem. The industry was shifting from lateral flow tests toward microfluidics-based diagnostics, and a design that worked on a lab bench could take one to two years to reach mass production. A patient feels that delay directly, as a test still sitting in a lab when they need it in a clinic. Lateral flow itself is broader than most people realize. It became known through COVID testing, but the same format is used in food safety, animal testing and criminal investigation. The next generation, sometimes called lateral flow 2.0, can even build a microchip into the cassette itself, which raises the cost of the manufacturing gap every year.
Closing the gap took four specific changes: identical dispensing tools on the bench and on the line; a validated process recipe that transfers from lab to production unchanged; shared data between R&D and production; and design consulting before a cassette is finalized, not after.
A faster machine does not close a fifteen-year gap. Removing the need to translate between the lab and the floor does.
I started a podcast for a similar reason. This industry is full of companies doing extraordinary work that never reaches a wider audience. Some of that work is already respected inside the industry and invisible outside it: rapid sepsis diagnostics, where thirty minutes instead of seventy-two hours changes what happens next for a patient, and new approaches to continuous monitoring for chronic conditions. Somebody needs to carry that story honestly, one conversation at a time, without turning it into a sales pitch.
The goal has not changed since I first walked onto a Ginolis line. Rapid, affordable diagnostics should be a normal part of healthcare, not a privilege. The work continues.
Kauko Väinämö
Kauko Väinämö is CEO of Ginolis, a precision automation company for microfluidics and diagnostics manufacturing based in Oulu, Finland, with over 150 production lines across 37 countries.